ArticleJournal for immunotherapy of cancer2023
Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy.
Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- A conserved grain-associated immunosuppressive niche in Sudanese patients with mycetoma.PLoS neglected tropical diseases · 2026Observational
- Targeting Post-Irradiation Thyroid Dysfunction: Electrospun Scaffolds As A Dual-Action Approach for Antioxidant and Immune Modulation.Advanced healthcare materials · 2026Article
- Single-Cell RNA-Seq Combined With Bulk RNA-Seq Revealed the Involvement of Pancreatic Cancer Tissue-Resident Macrophages in Tumour Progression and the Immunotherapy Response.Journal of cellular and molecular medicine · 2026Article
- Fibronectin Is a Likely Therapeutic Target Shared by Oral and Breast Carcinomas.International journal of molecular sciences · 2026Article
- Proof-of-principle 4-marker spatial profiling reveals distinct, location-independent immune clusters in biliary tract cancers.Pathology oncology research : POR · 2026Article
- Uncovering cellular perturbations and key mediator communications in liver cancer using single-cell RNA sequencing.Frontiers in immunology · 2026Article
- Immunity and Beyond: Emerging Roles of Monocytes and Macrophages in Cancer.Advances in experimental medicine and biology · 2026Review
- LGMNFrontiers in immunology · 2026Article
- Strategic trimodal therapy enhances radiation-induced abscopal response in renal cancer.Journal of translational medicine · 2025Article
- Functional remodeling of tissue-resident macrophages leads to distinct immune microenvironment evolution and clinical manifestations in lung adenocarcinoma.Clinical and experimental medicine · 2025Article
- Article
- Cellular plasticity and non-small cell lung cancer: role of T and NK cell immune evasion and acquisition of resistance to immunotherapies.Cancer metastasis reviews · 2025Review
- Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- Optimizing T cell inflamed signature through a combination biomarker approach for predicting immunotherapy response in NSCLC.Scientific reports · 2024Article
- Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Immunophenotypic Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A Cohort Study.Cancers · 2024Article
- Tissue-Resident Macrophages in Cancer: Friend or Foe?Cancer medicine · 2024Review
- SPI1Journal for immunotherapy of cancer · 2024Article
- PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer.Journal of experimental & clinical cancer research : CR · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary and secondary resistance is a major hurdle in cancer immunotherapy. Therefore, a better understanding of the underlying mechanisms involved in immunotherapy resistance is of pivotal importance to improve therapy outcome.
methodHere, two mouse models with resistance against therapeutic vaccine-induced tumor regression were studied. Exploration of the tumor microenvironment by high dimensional flow cytometry in combination with therapeutic
resultsComparison of the tumor immune infiltrate during early and late regression revealed a change from tumor-rejecting toward tumor-promoting macrophages. In concert, a rapid exhaustion of tumor-infiltrating T cells was observed. Perturbation studies identified a small but discernible CD163
conclusionsIn this study, a small population of CD163
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.